Full-Time
Develops treatments for neurodegenerative diseases
No salary listed
Senior
Cambridge, MA, USA
Candidates must reside in the United States, excluding Alaska, Arizona, Delaware, Hawaii, and Kansas. Expected to travel to the corporate location in Cambridge, MA several times a year.
Upload your resume to see how it matches 7 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently being tested in clinical trials, including the CENTAUR ALS trial, which showed significant benefits for ALS patients through a randomized, double-blind, placebo-controlled study. They are also conducting the PEGASUS trial to assess AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Lahar Mehta, M.D. Lahar Mehta, M.D., joins Nura Bio from Amylyx Pharmaceuticals, where he was Senior Vice President/Head, Global Clinical Development, leading clinical development and clinical pharmacology activities across several indications including amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and Wolfram syndrome.
On January 10, 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced its entry into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 17,142,857 shares of its common stock at a price of $3.50 per share.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 s
Amylyx Pharmaceuticals appoints Dan Monahan as Chief Commercial Officer.
Amylyx partners with Gubra for GLP-1 antagonist.